NCT04884399View on ClinicalTrials.gov

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

December 22, 2022

Study Completion Date

December 22, 2022

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

CMAB818

vascular endothelial growth factor (VEGF) inhibitor

DRUG

Lucentis®

vascular endothelial growth factor (VEGF) inhibitor

Trial Locations (4)

100044

Peking University People'S Hospital, Beijing

100730

Beijing Tongren Hospital, Beijing

200080

Shanghai General Hospital, Shanghai

430060

Renmin Hospital of Wuhan University, Wuhan

All Listed Sponsors
lead

Shanghai Biomabs Pharmaceutical Co., Ltd.

INDUSTRY